


## Germany

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Percapital	Change since previous	s survey: ▲ Improvement ▼ Decline	2009		2012		2015		2018
Organisation         Comprehensive Care Centres (CCCs)         Yes	International units	Factor VIII	6.82	•	6.07	<b>A</b>	7.34	<b>A</b>	7.98
of care         Haemophilia Treatment Centres National Haemophilia Council or Co-ordinating Group         Yes	per capita	Factor IX	0.97	•	0.70	_	0.85	•	0.83
National Haemophilia Council or Co-ordinating Group   No   A Yes   Yes   No   No   No   Number of groups in decision-making on haemophilia care   2   2   2   2   2   2   2   2   2	Organisation	Comprehensive Care Centres (CCC's)	Yes		Yes		Yes		Yes
Number of groups in decision-making on haemophilia care Number of groups choosing haemophilia treatment products National Tender for proups choosing haemophilia treatment products National Tender for proups choosing haemophilia treatment Products National Tender for proups choosing haemophilia treatment Products No Product Prestment Regimens % of people with haemophilia using home treatment Tender Prophylaxis treatment adilevered to the patient's home Prophylaxis treatment availability Pres Pes Pes Pes Pes Pes Pes Pes Pes Pes P	of care	Haemophilia Treatment Centres	Yes		Yes		Yes		Yes
Number of groups choosing haemophilia treatment products   No   No   No   No   No   No   No   N		National Haemophilia Council or Co-ordinating Group	No	<b>A</b>	Yes	▼	No		No
National Tender for procurement of factor concentrates   No   No   No   No   No   No   No   N		Number of groups in decision-making on haemophilia care	2		2	<b>A</b>	3		3
Treatment		Number of groups choosing haemophilia treatment products	2		2		2		2
Tegimens		National Tender for procurement of factor concentrates	No		No		No		No
Treatment delivered to the patient's home Prophylaxis treatment availability Yes Yes Yes Yes Yes Addits currently on prophy (%) 76-100% 76-100% 76-100% 76-100% Adults currently on prophy (%) 26-50% A 51-75% 51-75	Treatment	Home Treatment	Yes		Yes		Yes		Yes
Prophylaxis treatment availability Children currently on prophy (%) Adults currently on prophy (%) Adults currently on prophy (%) Access to IT (% of people with inhibitors) Access to Emergency medicine and acute surgery Access to Emergency medicine and acute surgery Paediatrics Infectious disease specialists (especially HiV) Access to Emergency medicine and acute surgery Paediatrics Infectious disease specialists (especially HiV) Access to Emergency medicine and acute surgery Paediatrics Infectious disease specialists (especially HiV) Access to Emergency medicine and acute surgery Paediatrics Infectious disease specialists (especially HiV) Access to Emergency medicine and acute surgery Paediatrics Infectious disease specialists (especially HiV) Access to Emergency Paediatrics Infectious disease specialists (especially HiV) Access to Emergency Paediatrics Infectious disease specialists (especially HiV) Access to Emergency Paediatrics Access to IT (% of people with inhibitors) Access to IT (% of people with inhibitors and soute sergers Access to IT (% of people with inhibitors) Access	regimens	% of people with haemophilia using home treatment	76-100%		76-100%		76-100%		76-100%
Children currently on prophy (%)		Treatment delivered to the patient's home	Unknown		No		No		Some
Adults currently on prophy (%) Access to III (% of people with inhibitors) Access to III (% of people with inhibitors) Access to Emergency medicine and acute surgery specialist services  Paediatrics Paediatrics Infectious disease specialists (especially HIV) Pes		Prophylaxis treatment availability	Yes		Yes		Yes		Yes
Access to ITI (% of people with inhibitors)  Access to Emergency medicine and acute surgery Specialist services  Paediatrics Infectious disease specialists (especially HIV) Yes		Children currently on prophy (%)	76-100%		76-100%		76-100%		76-100%
Access to Emergency medicine and acute surgery Paecilatics Paecila		Adults currently on prophy (%)	26-50%	<b>A</b>	51-75%		51-75%		51-75%
Paediatrics Infectious disease specialists (especially HIV) Pes Hepatology Rheumatology Orthopaedics Physiotherapy Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management Pain management Pain management General surgery Urology Prevalence Prevalence Prevalence Prevalence Prevalence Perevalence Perevalen		Access to ITI (% of people with inhibitors)	76-99%		76-99%	<b>A</b>	100%		100%
Infectious disease specialists (especially HIV)    Yes	Access to	Emergency medicine and acute surgery	Yes		Yes		Yes		Yes
Hepatology Rheumatology Orthopaedics Orthopaedics Physiotherapy Pes Physiotherapy Pes Physiotherapy Pes Physiotherapy Pes Physiotherapy Pes Physiotherapy Pes Pes Physiotherapy Pes Pes Physiotherapy Pes Pes Physiotherapy Pes	specialist services	Paediatrics	Yes		Yes		Yes		Yes
Rheumatology Orthopaedics Orthopaedics Physiotherapy Pes Pes Physiotherapy Pes Pes Pes Physiotherapy Pes		Infectious disease specialists (especially HIV)	Yes		Yes		Yes		Yes
Orthopaedics Physiotherapy Dentistry Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate WWD replacement Plasma DDAVP Plasma DDAVP Plasma Disparce Prevalence Ves Ves Ves Ves Ves Ves Ves Ves Ves Ve		Hepatology	Yes		Yes		Yes		Yes
Physiotherapy Dentistry Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Recombinant factor concentrate Cryoprecipitate  Plasma Physiotherapy Pes Yes Yes Yes Yes Yes Yes Yes Yes Yes Y		Rheumatology	Yes		Yes		Yes		Yes
Dentistry Obstetrics and Gynaecology Genetics Genetics Social and psychological support Pain management Pain management General surgery Urology Share of Expected Haemophilia A Bleeding Disorder Haemophilia Pasma-derived factor concentrate Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Cryoprecipitate  WWD replacement Plasma Persulaced Plasma Persulacenent Recombinant factor concentrate Recombinant factor concentrate Relways Plasma Persulacenent Recombinant factor concentrate Recombinant factor concentrate Rever		Orthopaedics	Yes		Yes		Yes		Yes
Obstetrics and Gynaecology Genetics Social and psychological support Pain management Pain mana		Physiotherapy	Yes		Yes		Yes		Yes
Genetics Social and psychological support Pain management Pain management Pain management Pain management General surgery Urology Yes		Dentistry	Yes		Yes		Yes		Yes
Social and psychological support Pain management Pais  Pais  Pain management Pais  Pais  Pain management Pais		Obstetrics and Gynaecology	Yes		Yes		Yes		Yes
Pain management General surgery Urology Yes		Genetics	Yes		Yes		Yes		Yes
General surgery Urology Yes		Social and psychological support	Yes		Yes	•	Sometimes		Sometimes
Urology  Yes Yes Yes Yes Yes Yes Yes Yes Yes Ye		Pain management	Yes		Yes		Yes		Yes
Share of Expected Haemophilia A Bleeding Disorder Haemophilia B Prevalence von Willebrand Disease 4% A 6% A 28% Haemophilia Pasma-derived factor concentrate Always		General surgery	Yes		Yes		Yes		Yes
Bleeding Disorder Prevalence		Urology	Yes		Yes		Yes		Yes
Prevalence von Willebrand Disease 4%	Share of Expected	Haemophilia A	61%	•	49%	•	46%	<b>A</b>	46%
Haemophilia Pasma-derived factor concentrate Always Always Always Always Always replacement Recombinant factor concentrate Always Always Always Always Always therapy Plasma Never Never Rarely Never	Bleeding Disorder	Haemophilia B	32%	▼	31%	▼	27%	<b>A</b>	28%
replacement Recombinant factor concentrate Always Always Always Always therapy Plasma Never Neve	Prevalence	von Willebrand Disease	4%	<b>A</b>	6%	•	4%	<b>A</b>	5%
therapy Plasma Never Nev	Haemophilia	Pasma-derived factor concentrate	Always		Always		Always		Always
Cryoprecipitate     Never     Never     Never     Never       VWD replacement     Plasma-derived factor concentrate     Always     Always     Always       therapy     DDAVP     Always     Always     Always       Plasma     Never     Never     Rarely     Never	replacement	Recombinant factor concentrate	Always		Always		Always		Always
VWD replacement       Plasma-derived factor concentrate       Always       Always       Always       Always       Always         b DDAVP       Always	therapy	Plasma	Never		Never	•	Rarely	<b>A</b>	Never
therapy DDAVP Always Always Plasma Never Never ▼ Rarely ▲ Never		Cryoprecipitate	Never		Never		Never		Never
Plasma Never ▼ Rarely ▲ Never	VWD replacement	Plasma-derived factor concentrate	Always		Always		Always		Always
Plasma Never ▼ Rarely ▲ Never	therapy	DDAVP	Always		Always				Always
Cryoprecipitate Never Never Never Never Never		Plasma	Never		•	•	Rarely	<b>A</b>	-
		Cryoprecipitate	Never		Never		Never		Never